DAIICHI SANKYO ADR Aktie

 

AstraZeneca (AZN.US) and its partner Daiichi Sankyo (4568.JP) have received approval from US regulators for their precision medicine Datroway, which is intended for previously treated patients with advanced non-small cell lung cancer. This marks the first time such a therapy has been approved in the US for lung cancer treatment.......

LONDON (dpa-AFX) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan or Dato-DXd), co-deve......

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve their efficacy and safety....

LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L) Monday announced positive results from the DESTINY-Breast09 Phase III study evaluating Enhertu, co-developed with Daiichi Sankyo Company Limited (DSKYF.P......

AstraZeneca Plc and Daiichi Sankyo Co.'s Enhertu delayed the advance of a common type of breast cancer by more than a year in a large study, a result that may lead to expanded use of the medicine....

LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L) and Daiichi Sankyo (DSKYF.PK) announced that positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU (trastuzumab deruxtecan) demonstra......

KENILWORTH (NJ) (dpa-AFX) - The Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan, co-developed by Merck & Co Inc. (MRK) and Daiichi Sankyo Company, Limited......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

KENILWORTH (NJ) (dpa-AFX) - Merck & Co., Inc. (MRK), in collaboration with Daiichi Sankyo, Monday has announced that the first patient has been dosed in the Phase 3 IDeate-Esophageal01 trial. This......

LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L) and Daiichi Sankyo Company Limited (DSKYF.PK) Wednesday reported positive results from the DESTINY-Breast11 Phase III study of Enhertu. The study met its......

07 May 2025 Enhertufollowed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial AstraZeneca and Daiichi Sankyo's Enhertu followed by THP showed an improved safety profile vs. standard of care First Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel,...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

TOKYO (dpa-AFX) - Daiichi Sankyo Company Limited (DSKYF.PK) revealed a profit for its full year that increased from the same period last yearThe company's bottom line totaled JPY295.756 billion, o......

This announcement contains inside information   22 April 2025   Enhertu plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive metastatic breast cancer   DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo's Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care   Positive high-level results from...

LONDON (dpa-AFX) - Daiichi Sankyo Co., Ltd. (DSKYF.PK) announced Monday that Enhertu (trastuzumab deruxtecan), co-developed and commercialized with British drug major AstraZeneca Plc. (AZN.L, AZN)......

SEATTLE, April 15, 2025 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company targeting RNA with small molecules, announced today a collaboration with Daiichi Sankyo focused on a key neurodegeneration target. Wayfinder's proprietary technology discovers potent, selective, and......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

LONDON (dpa-AFX) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced br......

04 April 2025 Enhertu approved in the EU as first HER2-directed therapy for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings AstraZeneca and Daiichi Sankyo's Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease AstraZeneca...

On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in direct competition with another Japanese pharmaceutical company, Daiichi Sankyo, in the TGCT......